Showing results (51-60 of 88) with videos related to
Sort By:
Pageof 9
Annals of Hematology|November 5, 2014
Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trialChristoph Röllig, Kerstin Schäfer-Eckardt, Matthias Hänel, et al.Lancet (London, England)|August 11, 2012
Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised studyHannes Wandt, Kerstin Schaefer-Eckart, Knut Wendelin, et al.Plos One|January 10, 2013
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot studyUtz Krug, Anja Koschmieder, Daniela Schwammbach, et al.Blood|April 12, 2012
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationNicola Gökbuget, Daniel Stanze, Joachim Beck, et al.Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2015
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITDAnthony D Ho, Johannes Schetelig, Tilmann Bochtler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trialMarkus Schaich, Stefani Parmentier, Michael Kramer, et al.Cancer Medicine|June 14, 2021
Preinfection laboratory parameters may predict COVID-19 severity in tumor patientsAlexander Kiani, Romina Roesch, Clemens M Wendtner, et al.Haematologica|July 8, 2008
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)Arcangelo Liso, Filippo Castiglione, Antonio Cappuccio, et al.Annals of Hematology|December 23, 2022
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study groupSteffen Koschmieder, Susanne Isfort, Dominik Wolf, et al.Pageof 9